Page 1

X4 PHARMACEUTICALS X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update August 6 , 2026 - Strengthened Clinical Operations to Continue Progress in Enrolling Global 4WARD Phase 3 Chronic Neutropenia Trial - - European Commission Approval of XOLREMDIⓇ ( Mavorixafor ) Provides the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway into 2029 - BOSTON , Aug. 06 , 2026 ( GLOBE NEWSWIRE ) -- X4 Pharmaceuticals ( Nasdaq : XFOR ) , a company focused on improving the lives of people with rare hematology diseases , today reported financial results for the second quarter ended June 30 , 2026 and provided a corporate update . " Since we began leading X4 last August , we have taken meaningful actions to strengthen the execution of the mavorixafor Phase 3 4WARD trial in chronic neutropenia , positioning 4WARD for the successful completion of enrollment , " said Adam Craig , M.D. , Ph.D. , Executive Chairman of X4 Pharmaceuticals . " Following our complete overhaul of the clinical operating infrastructure and engagement of a top oncology Clinical Research Organization ( CRO ) to manage the Phase 3 trial , we are now in a position to revisit the sample size of the study with the FDA . We expect to provide an update on our meeting with the FDA and the completion of enrollment by the end of the third quarter . " " Alongside these operational improvements , we continue to actively engage with the medical community to educate physicians on the potential benefits of mavorixafor as an improved treatment option for patients , including a strong presence at this year's EHA Congress . During the quarter , we also achieved an important milestone with the European Commission's marketing authorization of XOLREMDIⓇ for WHIM syndrome , supporting the therapeutic potential of mavorixafor across rare hematologic conditions , " concluded , Dr. Craig . Recent Accomplishments and Updates • Transitioned management of the Phase 3 4WARD trial to a premier Clinical Research Organization ( CRO ) to further strengthen the study execution and support completion of enrollment . • Advanced enrollment in the global 4WARD Phase 3 trial of oral , once - daily mavorixafor ( with or without G - CSF ) in patients with congenital , acquired primary autoimmune , or idiopathic chronic neutropenia , supported by several targeted initiatives including activation of over 110 active clinical trial sites worldwide , ongoing Medical Affairs engagement , and utilizing data - driven approaches to identify potential participants . • Continued to expand awareness in the medical community with a strong presence at the European Hematology Association ( EHA ) Congress including a publication entitled , " A Pivotal Phase 3 Study To Investigate Efficacy , Safety , and Tolerability of Mavorixafor in Participants with Primary Chronic Neutropenia " . The Medical Affairs team also hosted a booth and held an investigator meeting to engage with physicians regarding the 4WARD trial and the potential benefits of mavorixafor in chronic neutropenia . • Received marketing authorization for XOLREMDIⓇ ( mavorixafor ) by the European Commission for the treatment of patients with WHIM syndrome in the European Union ( EU ) . The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) . European commercialization will be led by X4 Pharmaceuticals ' partner , Norgine . In July 2026 , the EU marketing authorization was transferred to Norgine . Under the terms of the license and supply agreement , X4 could receive up to an additional € 221 million contingent upon the achievement of certain regulatory and commercial milestones , in addition to escalating double - digit royalties of up to the mid - twenties on any future net sales in the licensed territories . First Quarter Financial Results • Cash Position : As of June 30 , 2026 , the Company's cash position was $ 208.0 million . • Revenue : Revenue was $ 8.8 million and $ 11.5 million for the three and six months ended June 30 , 2026 , respectively . Revenue included net product sales of $ 2.4 million and $ 4.8 million for the three and six months ended June 30 , 2026 , respectively , attributable to XOLREMDIⓇ product sales in the United States . License and other revenue for the three and